![Olivier Bogillot](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 27 071 $ al 31/07/2026
Olivier Bogillot is currently Chairman at Sanofi Pasteur Merieux SAS since 2020.
Formerly, Dr. Bogillot was Chairman & Chief Executive Officer at Sanofi-Aventis France SA and President & Director at Provention Bio, Inc. Dr. Bogillot earned a doctorate from the University of Lyon.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CLARIANE SE 0 % | 31/12/2025 | 5.897 ( 0 % ) | 27 071 $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CLARIANE SE | Director/Miembro de la Junta | 14/05/2025 |
Sanofi Pasteur Merieux SAS
 Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Engages in activities of holding companies | Presidente | 01/03/2020 |
| Empresas | Cargo | Fin |
|---|---|---|
Sanofi-Aventis France SA
 Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Director Ejecutivo | - |
| PROVENTION BIO, INC. | Presidente | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Clariane SE
 Clariane SE Medical/Nursing ServicesHealth Services Operates retirement homes | Health Services |
University of Lyon
 University of Lyon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi Pasteur Merieux SAS
Sanofi Pasteur Merieux SAS Financial ConglomeratesFinance Engages in activities of holding companies | Finance |
Sanofi-Aventis France SA
Sanofi-Aventis France SA Medical DistributorsDistribution Services Wholesales pharmaceutical products | Distribution Services |
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company that engages in intercepting and preventing immune-mediated diseases including type 1 diabetic activities | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
